Cervical Cancer Clinical Trial
— APACHE-2Official title:
Attitudes to Different Strategies Among Women Not Attending Cervical Cancer Screening: Further Invitation by Mail or Kit for Self-collected Vaginal Sample
Scientific Context:
High-risk types of human papillomavirus (HPV) are the causative agents for cervical cancer.
Cervical cancer screening strategies rely on periodic Papanicolaou (Pap) testing. It's
well-known that this test has significantly contributed to the reduction of mortality and
morbidity due to cervical cancer. In France, it now seems that the screening strategy could
be optimized. The two main ways are to reach the 7 million underscreened women (organized
screening, self-sampling for HPV DNA testing) and to improve the screening test (HPV DNA
testing, computer-assisted cytology). Self-collected vaginal samples (SCVS) for HPV DNA
testing could be a relevant screening option: this technique appears reliable and it could
allow to reach women who are never or seldom screened. The performance of the SCVS to detect
cervical HPV infection has been assessed by the first part of the whole study: APACHE-1.
The goal of this study is to compare the attitudes of women not attending organized cervical
cancer screening face to different strategies: further invitation to make a cervical smear
or kit for self-collected vaginal sample sent at home.
Description of the project :
Nine months after a primary invitation to make a cervical smear, a random sample of 6000
women not attending organized cervical cancer screening will be randomly assigned to one of
the following arms:
- Intervention arm 1:
Women will receive a further invitation to make a cervical smear
- Intervention arm 2:
Women will be directly sent the kit for self-collected vaginal sample at home. The women who
will send the self-sample to the laboratory for analyse will receive their results at home
as well as their general practitioner if the HPV DNA test is positive (infection by a
high-risk HPV).
For them who will have a HPV DNA test positive, it will be necessary to complete the
screening action with a cervical smear. That's why those women will receive an invitation to
make a cervical smear if they won't do it during the 9 months following the first mail.
- Control arm: Those women will receive complete information about the study, the main
results and the screening recommendations at the end of the study.
Status | Completed |
Enrollment | 5998 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 30 Years to 65 Years |
Eligibility |
Inclusion Criteria : - Women from 30 to 65 years - Living in Indre-et-Loire (french territorial division 37) Exclusion Criteria : - Women who attend organized cervical cancer screening or who answer to the invitation - Cervical smear made in the three last years - HPV linked cervical condition undergoing treatment - Hysterectomy (including cervix) |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Tours |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of women's attitude according to the arm: participation or not to a whole screening action | Comparison of attitudes among women not attending organized cervical cancer according to the type of intervention or the lack of intervention: participation or not to a whole screening action. Are considered as whole screening action: cervical smear HPV DNA testing on self-collected vaginal sample negative (no infection by a high-risk HPV) HPV DNA testing on self-collected vaginal sample positive (infection by a high-risk HPV) followed by a cervical smear |
9 months after the beginning of the study (sending of mails) | No |
Secondary | Analysis in sub-groups | Analysis in sub-groups in order to compare the efficacy of interventions according to : The age Health insurance system Distribution map (urban area, peri-urban area, rural area) |
9 months after the beginning of the study (sending of mails) | No |
Secondary | Identification of the psychological determinants and mechanisms (checks and motivational factors) | Identify the psychological determinants and mechanisms (checks and motivational factors) that can affect enrollment to the screening procedure for self-collection vaginal sample or cervical smear. Nine months after the beginning of the study, a questionnaire will be send to the 6000 women. |
9 months after the beginning of the study (sending of mails) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |